China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version).
10.3779/j.issn.1009-3419.2023.102.10
- Collective Name:Chinese Expert Group on Early Diagnosis and Treatment of Lung Cancer;China Lung Oncology Group
- Publication Type:Journal Article
- Keywords:
Guideline;
Low-dose computed tomography;
Lung neoplasms;
Screening
- MeSH:
Humans;
Lung Neoplasms/epidemiology*;
Early Detection of Cancer/methods*;
Artificial Intelligence;
Mass Screening/methods*;
Tomography, X-Ray Computed/methods*;
China/epidemiology*
- From:
Chinese Journal of Lung Cancer
2023;26(1):1-9
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer-related death in China. The effectiveness of low-dose computed tomography (LDCT) screening has been further validated in recent years, and significant progress has been made in research on identifying high-risk individuals, personalizing screening interval, and management of screen-detected findings. The aim of this study is to revise China national lung cancer screening guideline with LDCT (2018 version). The China Lung Cancer Early Detection and Treatment Expert Group (CLCEDTEG) designated by the China's National Health Commission, and China Lung Oncolgy Group experts, jointly participated in the revision of Chinese lung cancer screening guideline (2023 version). This revision is based on the recent advances in LDCT lung cancer screening at home and abroad, and the epidemiology of lung cancer in China. The following aspects of the guideline were revised: (1) lung cancer risk factors besides smoking were considered for the identification of high risk population; (2) LDCT scan parameters were further classified; (3) longer screening interval is recommended for individuals who had negative LDCT screening results for two consecutive rounds; (4) the follow-up interval for positive nodules was extended from 3 months to 6 months; (5) the role of multi-disciplinary treatment (MDT) in the management of positive nodules, diagnosis and treatment of lung cancer were emphasized. This revision clarifies the screening, intervention and treatment pathways, making the LDCT screening guideline more appropriate for China. Future researches based on emerging technologies, including biomarkers and artificial intelligence, are needed to optimize LDCT screening in China in the future.
.
